| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $23.50 | Neutral | Redburn Atlantic |
| 3/24/2025 | $25.00 | In-line | Evercore ISI |
| 1/6/2025 | $21.00 → $26.00 | Neutral → Overweight | Piper Sandler |
| 12/12/2024 | $25.00 → $24.00 | Buy → Hold | Deutsche Bank |
| 9/24/2024 | $27.00 | Buy | Jefferies |
| 9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/28/2024 | $21.00 | Neutral | Citigroup |
| 4/11/2024 | $18.00 | Underperform | Bernstein |
| 4/3/2024 | Mkt Perform | William Blair | |
| 3/1/2024 | $20.00 | Neutral | Goldman |
Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as
Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa
Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in
Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced a five-year collaboration with Microsoft which aims to establish a strong foundation for transforming digital operations through advanced Artificial Intelligence (AI) technologies. These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to set new standards for innovation across commercial, operations, and technology practices ultimately delivering enhanced consumer experiences, increased productivity, and sustained growth. Over the next
New campaign introduces new Bond Protein Repair hair line designed to deliver effective bonding repair – at a fraction of the price of prestige brands SUMMIT, N.J., April 7, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) announces actress and entrepreneur, Shay Mitchell, as the global brand ambassador for OGX®, stepping in as the face of the brand's Fixer character in their new campaign. This collaboration marks an exciting new chapter for OGX®, as the brand leans deeper into its positioning as #1 in hair repairi, with The Fixer as a character embodying that expertise, and leverages the power of science-backed, expert-endorsed innovations to reach more consumers.
The Brand's Latest Mineral Sunscreen AddressesTop Consumer Barriers to Daily Sunscreen Use SUMMIT, N.J., March 31, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE:KVUE) continues to push the boundaries of suncare product development with the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. A December 2024 Kenvue research study found that 99% of healthcare providers believe if sunscreen offered better application and aesthetic experiences, patients would use their sunscreen more often1. The new mineral formula addresses these barriers by offering a high SPF with a lightweight, invisible finish. To raise awareness, the #1 suncare brand2 in the U.S. is launching a new campai
Science Behind Iconic Brands, including NEUTROGENA® and AVEENO®, Underscores the Company's Expertise and Commitment to Shaping the Future of Skin Health & Beauty Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry experts on the effectiveness of formulations behind iconic brands such as
Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as
Kenvue Inc. (NYSE:KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-bac
Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% Q4 Diluted EPS was $0.15; Adjusted Diluted EPS1 was $0.26 FY'24 Net Sales Increased 0.1% to $15.5 Billion; Organic Sales1 Grew 1.5% FY'24 Gross Profit Margin Improved 200 Basis Points and Our Vue Forward Savings Supported Increased Marketing Investment to Fuel Growth FY'24 Diluted EPS was $0.54; Adjusted Diluted EPS1 was $1.14 Provides Outlook for FY'25 Kenvue Inc. (NYSE:KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we
Company Confirms Receipt of Director Nominees from Starboard Value No Shareholder Action Required at This Time Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today issued the following statement in response to Starboard Value's ("Starboard") submission of four nominees to stand for election to the Kenvue Board of Directors at Kenvue's 2025 Annual Meeting of Shareholders: The Kenvue Board and management team are committed to acting in the best interests of Kenvue and our shareholders. We engage regularly with our shareholders and are open to constructive dialogue with and suggestions from Kenvue shareholders. We note that members o
Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50
Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00
Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously
Deutsche Bank downgraded Kenvue from Buy to Hold and set a new price target of $24.00 from $25.00 previously
Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00
RBC Capital Mkts downgraded Kenvue from Outperform to Sector Perform and set a new price target of $24.00
Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00
Bernstein initiated coverage of Kenvue with a rating of Underperform and set a new price target of $18.00
William Blair initiated coverage of Kenvue with a rating of Mkt Perform
Goldman resumed coverage of Kenvue with a rating of Neutral and set a new price target of $20.00
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in
Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% Q4 Diluted EPS was $0.15; Adjusted Diluted EPS1 was $0.26 FY'24 Net Sales Increased 0.1% to $15.5 Billion; Organic Sales1 Grew 1.5% FY'24 Gross Profit Margin Improved 200 Basis Points and Our Vue Forward Savings Supported Increased Marketing Investment to Fuel Growth FY'24 Diluted EPS was $0.54; Adjusted Diluted EPS1 was $1.14 Provides Outlook for FY'25 Kenvue Inc. (NYSE:KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we
Company Confirms Receipt of Director Nominees from Starboard Value No Shareholder Action Required at This Time Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today issued the following statement in response to Starboard Value's ("Starboard") submission of four nominees to stand for election to the Kenvue Board of Directors at Kenvue's 2025 Annual Meeting of Shareholders: The Kenvue Board and management team are committed to acting in the best interests of Kenvue and our shareholders. We engage regularly with our shareholders and are open to constructive dialogue with and suggestions from Kenvue shareholders. We note that members o
Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every d
Net Sales Decreased 0.4% to $3.9 Billion; Organic Growth1 was 0.9% Gross Profit Margin Expansion and Our Vue Forward Savings Fuel Increased Marketing Investment Diluted EPS was $0.20; Adjusted Diluted EPS1 was $0.28 Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal third quarter ended September 29, 2024. "During the third quarter, we continued to drive strong productivity and realize efficiency benefits from Our Vue Forward, which we are reinvesting behind our iconic brands to unleash the full potential of our business and fulfill our commitment to create long-term shareholder value," said Thibaut Mongon, Chief Executive Officer. "This reinvestment
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its third quarter 2024 financial results before market open on November 7, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage,
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on November 27, 2024, to shareholders of record as of the close of business on November 13, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe
Net Sales of $4.0 Billion decreased 0.3%; Organic Growth1 was +1.5% Diluted EPS was $0.03; Adjusted Diluted EPS1 was $0.32 Productivity gains fuel accelerated investment in brands for future growth Reaffirms Outlook for FY24 Net Sales Growth and Adjusted Diluted EPS Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal second quarter ended June 30, 2024. "We are on track to deliver the financial targets we set for 2024, and while we are in the early days, our work to transform Kenvue into a bolder, more agile organization focused on profitable growth is producing results," said Thibaut Mongon, Chief Executive Officer. "With the progress we ha
DEFA14A - Kenvue Inc. (0001944048) (Filer)
DEF 14A - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
S-3ASR - Kenvue Inc. (0001944048) (Filer)
10-K - Kenvue Inc. (0001944048) (Filer)
SCHEDULE 13G - Kenvue Inc. (0001944048) (Subject)
8-K - Kenvue Inc. (0001944048) (Filer)
PREC14A - Kenvue Inc. (0001944048) (Subject)
10-Q - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)